Objectives: Bedaquiline (BDQ) is the first new anti-tuberculosis (TB) drug
introduced to the market after 45 years. Recent studies have shown the
potential benefits of adding bedaquiline to regimens for drug-resistant TB
(DR-TB). In search of more effective regimens for DR-TB, bedaquiline was
introduced in the TB program in the Philippines under operational research to
assess its effectiveness, safety, and tolerability when given with background
regimens among patients with multi-or extensively DR-TB (MDR/XDR-TB). Design: A prospective cohort study of patients with MDR/XDR-TB was given with a
bedaquiline-containing regimen from June 2016 to May 2017. Demographic data,
presence of comorbidities, and microbiologic profile on entry were recorded.
Bedaquiline was administered at the recommended dose of 400 mg once daily for
14 days, then 200 mg three times a week for 22 weeks together with World Health
Organization (WHO)-compliant background regimen. The time to culture
conversion, interim outcomes at the 6th month of treatment, end-of-treatment
outcomes, and post-treatment follow-up outcomes after one year was determined.
The frequency and severity of adverse events (SAE) were recorded as part of
pharmacovigilance. Results: Seventy-five patients were given with
bedaquiline-containing regimen during the study period. Forty-two (56.0%) had
second-line injectable resistance, 23 (30.7%) had fluoroquinolone-resistance, 6
(8.0%) had MDR-TB, and 4 (5.3%) had XDR-TB. In the 6th month of post-enrolment, 79% were
culture-negative. The treatment success rate was 65.3% (37 were
cured and 12 completed treatment), 7 (9.3%) died, 17 (22.7%) lost to follow-up,
and 2 (2.7%) were withdrawn from treatment. Adverse events included vomiting
(80%), dizziness (69%), nausea (52%), cough (44%), and headache
References
[1]
World Health Organization (2017) Global Tuberculosis Report 2017. World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/259366
[2]
Department of Health-National TB Control Program (2016) National Tuberculosis Prevalence Survey 2016 Philippines. Department of Health-Disease Prevention and Control Bureau, Manila. https://ntp.doh.gov.ph/download/national-tuberculosis-prevalence-survey-2016
[3]
World Health Organization (2018) Global Tuberculosis Report 2018. WHO/CDS/ TB/2018.20, World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/274453
[4]
Department of Health-National TB Control Program (2016) NTP Cohort Analysis. Department of Health-Disease Prevention and Control Bureau, Manila.
[5]
Tupasi, T., Garfin, A., Kurbatova, E., Mangan, J., Orillaza-Chi, R., Naval, L., et al. (2016) Factors Associated with Loss to Follow-Up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014. Emerging Infectious Diseases, 22, 491-502. https://doi.org/10.3201/eid2203.151788
[6]
World Health Organization (2013) The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis, Interim Policy Guidance. World Health Organization, Geneva. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf
[7]
Gras, J. (2013) Bedaquiline for the Treatment of Pulmonary, Multidrug-Resistant Tuberculosis in Adults. Drugs Today, 29, 353-361.
[8]
World Health Organization (2008) Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Emergency Update 2008. World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/43965
[9]
National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. NIH Publication. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
[10]
Pontali, E., Sotgiu, G., D’Ambrosio, L., Centis, R. and Migliori, G.B. (2016) Bedaquiline and Multidrug-Resistant Tuberculosis: A Systematic and Critical Analysis of the Evidence. European Respiratory Journal, 47, 394-402. https://doi.org/10.1183/13993003.01891-2015
[11]
Borisov, S.E., Dheda, K., Enwerem, M., Leyet, R.R., D’Ambrosio, L., Centis, R., et al. (2017) Effectiveness and Safety of Bedaquiline-Containing Regimens in the Treatment of MDR and XDR TB: A Multicentre Study. European Respiratory Journal, 49, Article ID: 1700387. https://doi.org/10.1183/13993003.00387-2017
[12]
Falzon, D., Schünemann, H.J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., et al. (2016) World Health Organization Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. European Respiratory Journal, 49, Article ID: 1602308. https://doi.org/10.1183/13993003.02308-2016
[13]
World Health Organization (2018) WHO Treatment Guidelines for Rifampicin- and Multidrug-Resistant Tuberculosis, 2018 Update. World Health Organization, Geneva. https://www.who.int/news-room/events/detail/2018/07/16/default- calendar/who-treatment-guidelines-for-rifampicin--and-multidrug-resistant-tuberculosis-2018-update
[14]
Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., et al. (2012) Multidrug-Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-Analysis of 9,153 Patients. PLOS Medicine, 9, e1001300.
[15]
Cegielski, J.P., Kurbatova, E., Van der Walt, M., Brand, J., Ershova, J., Tupasi, T., et al. (2016) Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial versus Acquired Second-Line Drug Resistance. Clinical Infectious Diseases, 62, 418-430. https://doi.org/10.1093/cid/civ910
[16]
Ndjeka, N., Schnippel, K., Master, I., Meintjes, G., Maartens, G., Romero, R., et al. (2018) High Treatment Success Rate for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Using a Bedaquiline-Containing Treatment Regimen. European Respiratory Journal, 52, Article ID: 1801528. https://doi.org/10.1183/13993003.01528-2018
[17]
Guglielmetti, L., Jaspard, M., Le Dû, D., Lachatre, M., Marigot-Outtandy, D., Bernard, C., et al. (2017) Long-Term Outcome and Safety of Prolonged Bedaquiline Treatment for Multidrug-Resistant Tuberculosis. European Respiratory Journal, 49, Article ID: 1601799. https://doi.org/10.1183/13993003.01799-2016
[18]
Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., et al. (2019) Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 25, 936-943. https://doi.org/10.3201/eid2505.181823
[19]
Diacon, A.H., Pym, A., Grobusch, M.P., De Los Rios, J., Gotuzzo, E., Vasilyeva, I., et al. (2014) Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. The New England Journal of Medicine, 371, 723-732. https://doi.org/10.1056/NEJMoa1313865
[20]
Diacon, A.H., Pym, A., Grobusch, M.P., Patientia, R., Rustomjee, R., Page-Shipp, L., et al. (2009) The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. The New England Journal of Medicine, 360, 2397-2405. https://doi.org/10.1056/NEJMoa0808427
[21]
Diacon, A.H., Donald, P.R., Pym, A., Grobusch, M., Patientia, R.F., Mahanyele, R., et al. (2012) Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance. Antimicrobial Agents and Chemotherapy, 56, 3271-3276. https://doi.org/10.1128/AAC.06126-11
[22]
Sagwa, E., Mantel-Teeuwisse, A.K., Ruswa, N., Musasa, J.P., Pal, S., Dhliwayo, P., et al. (2012) The Burden of Adverse Events during Treatment of Drug-Resistant Tuberculosis in Namibia. Southern Med Review, 5, 6-13.
[23]
Bloss, E., Kuksa, L., Holtz, T.H., Riekstina, V., Skripconoca, V., Kammerer, S., et al. (2010) Adverse Events Related to Multidrug-Resistant Tuberculosis Treatment, Latvia, 2000-2004. The International Journal Tuberculosis and Lung Disease, 14, 275-281.
[24]
Keshavjee, S., Gelmanova, I.Y., Shin, S.S., Mishustin, S.P. andreev, Y.G., Atwood, J.J., et al. (2012) Hepatotoxicity during Treatment for Multidrug-Resistant Tuberculosis: Occurrence, Management and Outcome. The International Journal Tuberculosis and Lung Disease, 16, 596-603. https://doi.org/10.5588/ijtld.11.0591
[25]
Pontali, E., D’Ambrosio, L., Centis, R., Sotgiu, G. and Battista, G.M. (2017) Multidrug-Resistance Tuberculosis and Beyond: An Updated Analysis of the Current Evidence on Bedaquiline. European Respiratory Journal, 49, Article ID: 1700146. https://doi.org/10.1183/13993003.00146-2017
[26]
Dalcolmo, M., Gayoso, R., Sotgiu G., D’Ambrosio, L., Rocha, J.L., Borga, L., et al. (2017) Effectiveness and Safety of Clofazimine within a Standard Multidrug-Resistant Tuberculosis: A Nationwide Report from Brazil. European Respiratory Journal, 49, Article ID: 1602445. https://doi.org/10.1183/13993003.02445-2016
